Published in Ann Rheum Dis on May 01, 2002
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
Ankylosing spondylitis: an overview. Ann Rheum Dis (2002) 2.71
Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis (2004) 1.49
Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis (2003) 1.31
Validity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis. Arthritis Res Ther (2010) 1.26
[Burden of illness. First routine report on socio-medical consequences of inflammatory rheumatic disease in Germany]. Z Rheumatol (2008) 1.26
Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity. Ann Rheum Dis (2005) 1.21
Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res (2002) 1.21
Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis (2004) 1.07
Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis (2006) 1.04
Costs of ankylosing spondylitis in three European countries: the patient's perspective. Ann Rheum Dis (2003) 0.99
Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis. Ann Rheum Dis (2006) 0.95
Ankylosing spondylitis: introductory comments on its diagnosis and treatment. Ann Rheum Dis (2002) 0.90
[Structures of acute rheumatic care]. Z Rheumatol (2006) 0.89
Whole body MR imaging in ankylosing spondylitis: a descriptive pilot study in patients with suspected early and active confirmed ankylosing spondylitis. BMC Musculoskelet Disord (2007) 0.88
Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis (2005) 0.88
Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech Republic. Clin Rheumatol (2008) 0.85
Patients with ankylosing spondylitis have increased sick leave--a registry-based case-control study over 7 yrs. Rheumatology (Oxford) (2009) 0.84
A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis. Mod Rheumatol (2011) 0.82
The Cost of Ankylosing Spondylitis in the UK Using Linked Routine and Patient-Reported Survey Data. PLoS One (2015) 0.81
Outcomes in ankylosing spondylitis: what makes the assessment of treatment effects in ankylosing spondylitis different? Ann Rheum Dis (2006) 0.81
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 9 International classification of functioning, disability and health (ICF)]. Z Rheumatol (2014) 0.81
Socioeconomic impact of ankylosing spondylitis in Morocco. Clin Rheumatol (2007) 0.80
Is avoidant coping independent of disease status and stable over time in patients with ankylosing spondylitis? Ann Rheum Dis (2004) 0.79
Direct and indirect costs associated with ankylosing spondylitis and related disease activity scores in Turkey. Rheumatol Int (2015) 0.79
Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey. Arthritis Res Ther (2016) 0.78
[Effectiveness and safety of radium chloride in the treatment of ankylosing spondylitis. Results of an observational study]. Z Rheumatol (2006) 0.75
The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008. Rheumatol Int (2013) 0.75
Costs of Drug Therapy in Patients with Ankylosing Spondylitis in Brazil. Rheumatol Ther (2016) 0.75
Analysis on the situation of subjective well-being and its influencing factors in patients with ankylosing spondylitis. Health Qual Life Outcomes (2016) 0.75
Is the work ability index useful to evaluate absence days in ankylosing spondylitis patients? A cross-sectional study. BMJ Open (2013) 0.75
Health care costs associated with ankylosing spondylitis in Turkey: an analysis from nationwide real-world data. Int J Rheumatol (2013) 0.75
There's more to life than everyday function: the challenge of measuring social role participation in ankylosing spondylitis. Nat Clin Pract Rheumatol (2009) 0.75
Cost-of-illness and quality of life in patients with ankylosing spondylitis at a tertiary hospital in Korea. J Korean Med Sci (2014) 0.75
Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis. BMJ Open (2016) 0.75
Work productivity is associated with disease activity and functional ability in Italian patients with early axial spondyloarthritis: an observational study from the SPACE cohort. Arthritis Res Ther (2016) 0.75
Spectrum of ankylosing spondylitis in Portugal. Development of BASDAI, BASFI, BASMI and mSASSS reference centile charts. Clin Rheumatol (2011) 0.75
High frequencies of HLA-B27 in Chinese patients with suspected of ankylosing spondylitis. Rheumatol Int (2009) 0.75
Modeling valuations for EuroQol health states. Med Care (1997) 21.66
A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol (1994) 11.17
A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol (1994) 8.61
How should cost data in pragmatic randomised trials be analysed? BMJ (2000) 6.66
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum (1998) 6.16
A cost-of-illness study of back pain in The Netherlands. Pain (1995) 4.02
The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum (1984) 3.20
A practical guide for calculating indirect costs of disease. Pharmacoeconomics (1996) 3.08
Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol (2000) 2.45
Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) (2000) 2.40
Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in The Netherlands. Soc Sci Med (2000) 2.01
Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol (1997) 1.91
Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis (2001) 1.77
Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. J Rheumatol (2000) 1.67
Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum (2001) 1.65
Direct medical costs unique to people with arthritis. J Rheumatol (1997) 1.64
Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol (1997) 1.34
National database of patients visiting rheumatologists in The Netherlands: the standard diagnosis register of rheumatic diseases. A report and preliminary analysis. Br J Rheumatol (1998) 1.25
Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) (2001) 1.25
The cost of rheumatoid arthritis. Br J Rheumatol (1996) 1.14
An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol (1999) 1.08
A national study of medical care expenditures for musculoskeletal conditions: the impact of health insurance and managed care. Arthritis Rheum (2001) 1.06
The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs. Arthritis Rheum (1978) 1.04
Ankylosing spondylitis: a comparative study of patients in an epidemiological survey, and those admitted to a department of rheumatology. J Rheumatol (1984) 1.01
Socioeconomic costs of rheumatic diseases. Implications for technology assessment. Int J Technol Assess Health Care (2000) 0.94
Locomotion status and costs in destructive rheumatoid arthritis. A comprehensive study of 82 patients from a population of 13,000. Acta Orthop Scand (1992) 0.93
Indirect costs of disease; an international comparison. Health Policy (1995) 0.83
[The economic and social effects of rheumatoid pelvis-spondylitis]. Rev Epidemiol Sante Publique (1982) 0.83
Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) (2000) 22.00
OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage (2008) 10.99
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2003) 7.95
OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage (2010) 7.52
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24
Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol (1997) 5.09
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2004) 4.94
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.83
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum (2001) 4.57
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2000) 4.37
OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage (2007) 4.34
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage (2004) 4.01
Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis (2004) 3.95
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis (2003) 3.33
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis (2007) 3.31
Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage (1996) 3.26
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 3.17
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis (2009) 3.15
[Criteria of the classification of spondylarthropathies]. Rev Rhum Mal Osteoartic (1990) 3.04
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
How to diagnose axial spondyloarthritis early. Ann Rheum Dis (2004) 2.91
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis (2009) 2.76
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum (2008) 2.71
Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis -- results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage (2005) 2.69
Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis (2006) 2.68
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.66
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis (2008) 2.61
Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis (2004) 2.60
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis (2003) 2.48
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage (2000) 2.42
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis (2010) 2.40
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 2.37
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis (2008) 2.33
Management of osteoarthritis (OA) with an unsupervised home based exercise programme and/or patient administered assessment tools. A cluster randomised controlled trial with a 2x2 factorial design. Ann Rheum Dis (2004) 2.29
Factors determining inpatient satisfaction with care. Soc Sci Med (2002) 2.29
Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol (2014) 2.28
The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement. Osteoarthritis Cartilage (2010) 2.24
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol (1999) 2.21
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis (2004) 2.15
Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol (1999) 2.12
Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol (1997) 2.11
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis (2010) 2.09
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis (2005) 2.08